• CONTACT US: +92 51 8738362-5
  • EMAIL: [email protected]
  • ABOUT US
    • CORPORATE HISTORY –
    • BUSINESS PARTNERSHIPS –
    • QUALITY CONTROL & QUALITY ASSURANCE –
    • MANUFACTURING EXPERTISE –
    • MARKETING & SALES –
  • OUR DIVISIONS
    • PHARMA HEALTH DIVISION –
    • ANIMAL HEALTH DIVISION –
    • BIO-LABS CONSUMER HEALTH
  • PRODUCTS
    • ALL FEATURED BRANDS
    • PHARMA HEALTH PRODUCTS LIST
    • ANIMAL HEALTH PRODUCTS LIST
  • GLOBAL PRESENCE –
  • BIO-LABS SUBSIDIARIES –
    • Bio-Next Pharmaceuticals –
    • Bio-Labs Consumer Health –
    • ZH Therapeutics –
  • CSR –
  • NEWS & PRESS –
  • CAREERS –
  • CONTACT
0
  • Home
  • PHARMA HEALTH
  • Molnupiravir Capsules 200 mg
Bio-Maltose 50mg/ml Injection
October 22, 2021
Merobio IV Injection (Meropenem 500mg)
March 22, 2022
Show all
ANTI-ANEMIC

Molnupiravir Capsules 200 mg

SIZE:

40 capsules

COMPOSITION

Molnupiravir

Strength

200mg

ADD TO FAVOURITES
ADD TO FAVOURITES
Categories: Anti-viral, PHARMA HEALTH Tag: ANTI-ANEMIC
Share
Description

Composition

Molnupiravir 200mg Capsule

Highlights

  1. Reduces the risk of hospitalization in COVID-19 patients
  2. Convenient Oral Dosage
  3. Having a profound impact in controlling the pandemic
  4. A safe, affordable, and effective antiviral drug

 

Description

Molnucap (Molnupiravir) belongs to the class of antivirals termed as Mutagenic Ribonucleosides. It prevents the replication and transcription of the viral genomes by introducing errors and changes in viral genetic material.

Dosage and Administration

Molnucap (Molnupiravir) can be taken with or without food.

Adults

The recommended dosage of Molnucap (Molnupiravir) is 800mg, (four 200mg capsules) every 8 hours for 5 days.

The safety and efficacy of Molnucap (Molnupiravir), if taken more than 5 days, have not been established.

More Information

Elderly: No dose adjustment is required.

Renal Impairment: No dose adjustment is required.

Hepatic Impairment: No dose adjustment is required.

Pediatric Population: No data is available for the administration of Molnupiravir in patients below 18 years of age.

Pregnancy: Molnupiravir is not recommended during pregnancy. The women of childbearing potential should use effective contraception during the treatment and for 4 days after the last dose of Molnupiravir.

Contraindications:

Hypersensitivity to the active substance

Storage

Store at room temperature (up to 30°C)

Related products

  • Infectious Disease (ID Control Medication)

    LAZMA CREAM 15gm

    ₨222.00
  • Infectious Disease (ID Control Medication)

    MYVAN VIAL

    ₨225.00
  • Infectious Disease (ID Control Medication)

    IT-CAP CAPSULES

 

Bio-Labs is an innovative healthcare company expert in manufacturing and quality control of high-end pharmaceutical products.

  • Contact US: +92 51 8738362-5
  • EMAIL: [email protected]
  • ADDRESS: ISLAMABAD, PAKISTAN

QUICK LINKS

  • HOME
  • CORPORATE HISTORY
  • PHARMA HEALTH DIVISION
  • ANIMAL HEALTH DIVISION
  • PRODUCTS
  • NEWS & PRESS
  • CAREERS
  • CONTACT

RECENT POST

  • 0
    Bio-Labs Signed MOU with N-ovative Health Technologies (NHT), for cardiac stents & catheters
    June 14, 2022
  • 0
    Bio-Labs – Donated medicines to Sri Lanka
    June 7, 2022
  • 0
    Bio-Labs successfully launched Qualey (Quetiapine Fumarate) in it’s Psychiatry Division
    February 14, 2022

BIO-LABS SISTER CONCERNS

  • Bio-Next Pharmaceuticals
  • Bio-Labs Consumer Health
  • ZHTherapeutics
Copyrights © 2022 Bio-Labs | All rights reserved.